Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab with Induction Chemotherapy and Concurrent Chemoradiotherapy in HNSCC
NCT01326923Phase 2Terminated
- Sponsor
- LSU Health Shreveport
- Start
- Jun 2010
- Primary completion
- Feb 2014
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cetuximab in head and neck squamous cell carcinoma (HNSCC), sponsored by LSU Health Shreveport. Started Jun 2010; status: terminated.
02
Drugs
cetuximab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT01326923.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01326923.